A comprehensive geriatric assessment screening questionnaire (CGA-GOLD) for older people undergoing treatment for cancer Oncology services do not routinely assess broader needs of older people with cancer. This study evaluates a comprehensive geriatric assessment and comorbidity screening questionnaire (CGA-GOLD) covering evidence-based domains and quality of life (EORTC-QLQ-C30). Patients aged 65+ attending oncology services were recruited into (1) Observational cohort (completed CGA-GOLD, received standard oncology care), (2) Intervention cohort (responses categorised 'low-risk', 'high-risk', 'possible need' by geriatricians). N = 417 observational patients (1002 invited by post, 418 consented, age 73.9 AE 5.4) completed CGA-GOLD in 11.7 AE 7.9 min, 86.3% required no assistance, 3.1% overall missing responses. Multiple problems reported: hypertension (18.1%), diabetes (16.9%), dyspnoea on flat surfaces (27.6%), polypharmacy (46%), difficulty walking (14.9%), fatigue (40.5%), living alone (30.9%), social isolation (11.2%), recent functional dependence (27.8%), urinary incontinence (21.4%), falls (13.3%). 237/239 intervention patients completed CGA-GOLD and consecutive subsets examined. The doctor and nurse specialist independently identified same need level in 87.3% (high inter-rater reliability kappa = 0.80), taking 1-2 min per questionnaire. Need Original Article level remained unchanged following hospital notes review against responses in 90% (75/83). 'Possible need' patients were telephoned with change in 29% (16/55) to low-risk and none to high-risk, confirming high need was not being missed. CGA-GOLD screening questionnaire was acceptable to older patients, feasibly administered in NHS cancer services, described comorbidities, CGA and QOL needs, and reliably identified higher risk patients requiring further input for optimal cancer treatment.
INTRODUCTION
Thirty-six per cent of cancers in the UK are diagnosed in people aged 75+, and two-thirds are aged 65+ (Cancer Research UK 2009 . Older patients (defined as 65+) may have comorbidities, functional impairments and psychosocial factors which can affect decision making for cancer treatment (surgery, chemotherapy and radiotherapy), usually towards more conservative treatment (Department of Health 2013; Owen et al. 2014; Wildiers et al. 2014) . Crucially, such wider needs can be optimised and supported if identified early, improving cancer treatment tolerance and survival (McCorkle et al. 2000; Caillet et al. 2011; Hurria et al. 2012; Kalsi et al. 2015) .
Currently UK National Health Service (NHS) cancer services have little routine assessment beyond performance status assessment and clinical judgement of oncologists (Lund et al. 1990; Department of Health 2012) . The widely used European Cooperative Oncology Group Performance Status (ECOG-PS) has been validated in younger populations to prognosticate survival and chemotherapy toxicity (Lund et al. 1990; Gosney 2005 ), but there is less evidence in older patients (Gosney 2005) . ECOG-PS is a spot observation of physical function -level 2 ('requires some assistance') in an older patient may in fact relate to a number of treatable conditions. Use of brief tools without additional assessment in older people may lead to overestimation of comorbidity or frailty, and hence undertreatment of cancer (Extermann et al. 1998; Repetto et al. 2002) .
Comprehensive geriatric assessment (CGA) is a process that assesses and optimises comorbidities, and psychological and functional capabilities of an older person. CGA is a four stage process: (1) screening, (2) further assessment for those identified as having risk and needs, (3) needs-based management (may involve other disciplines, e.g. physiotherapy) and (4) follow-through to achieve patient-centred goals (Stuck et al. 1993) . Inpatient (Counsell et al. 2000; Ellis et al. 2011) ) and outpatient (Reuben et al. 1999) geriatrician-delivered CGA has been shown to reduce mortality, functional dependency and length of hospital stay, as have co-management models where geriatricians work with orthopaedic (Vidan et al. 2005) and surgical colleagues (Harari et al. 2007a,b) .
The US National Comprehensive Cancer Network, International Society of Geriatric Oncology (SIOG) and European Organisation for Research and Treatment of Cancer (EORTC) all recommend that some form of CGA screening is performed for all older cancer patients (Extermann et al. 2005; Pallis et al. 2010; Hurria et al. 2012) . While several oncological publications have investigated CGA, very few have evaluated the process beyond initial screening (Clough-Gorr et al. 2013; Wildiers et al. 2014) . Recent studies have demonstrated that geriatrician delivery of the full process (i.e. including optimisation) can influence oncology treatment decision making (Aliamus et al. 2011; Caillet et al. 2011 ) and improve patient outcomes with better chemotherapy tolerance (Kalsi et al. 2015) . Screening followed by in-depth assessment and management only for those at risk is now the paradigm of choice in the UK 5-year Cancer Strategy (2015) and oncological literature (Extermann et al. 2005; Gosney 2005; Hurria et al. 2012; Decoster et al. 2015) . Abbreviated screening tools have received scrutiny as they are quick to complete (approximately 5 min) but using such brief tools risks missing clinically important information. G-8 is the most studied (Bellera et al. 2012; Decoster et al. 2015) but lacks comorbidity assessment, an essential component as recommended by NCIN (2015) and EORTC (Pallis et al. 2011) . The EORTC Elderly Task Force recommended minimum data set for clinical trials includes G-8 but to be substantiated with comorbidities, function and social data (Pallis et al. 2011) .
Currently lacking in the CGA-oncology literature is a patient-reported screening tool that include more variables than abbreviated tools like G-8 but is sufficiently brief to be feasibly administered, and robust enough to identify needs and risk to trigger an effective management plan. Patient questionnaires have the benefit of highlighting patient concerns that will immediately inform the interaction and consultation between patient and provider in clinic. CGA patient questionnaires have been evaluated in oncology clinics (Ingram et al. 2002; Hurria et al. 2007; Clough-Gorr et al. 2013) and clinical trial settings (Hurria et al. 2011) in Europe and America, but these are lengthy assessments. Furthermore, this approach has not as yet been tested in the UK. The CGA-GOLD ('Comprehensive Geriatric Assessment-Geriatric-Oncology Liaison Development') patient questionnaire was therefore developed to provide a practical screening tool for use in busy cancer services and this study evaluates aspects of feasibility and validity.
METHODS

CGA-GOLD questionnaire development
The aim was to select an assessment tool that was short and easy enough to use, but sufficiently comprehensive to provide enough information about the patient to guide clinical decisions on need for further assessment or intervention. Equally as important is the ability of a tool to identify those patients who require no further intervention at the point of starting treatment. The CGA literature in older patients with and without cancer was reviewed to identify all tested domains as follows: physical function, comorbidities, medications, activities of daily living, mood, social situation, falls, nutrition, frailty, bladder and bowel problems (Extermann et al. 2005; Gosney 2005; Hurria et al. 2011) . A composite of evidence-based questions representing all of those domains from validated tools in the geriatric (Stuck et al. 1993; Reuben et al. 1999 , Counsell et al. 2000 Harari et al. 2008 ) and oncology literature (Extermann et al. 1998 (Extermann et al. , 2005 Ingram et al. 2002; Repetto et al. 2002; Gosney 2005; Hurria et al. 2005 Hurria et al. , 2012 were then included in the 2-page CGA-GOLD questionnaire. Quality of life is valued by older patients as a cancer treatment goal (Pinquart 2004 ) and although recommended as part of holistic assessment in the UK (NCSI 2015) is not systematically applied. The EORTC-QLQ-C30 was therefore incorporated into CGA-GOLD; it is cancer-specific, multidimensional and has been validated in older people including as a component of CGA screening (Aaronson 1993; Pallis et al. 2011) . A Plan Do Study Act consultation was conducted with 10 consecutive patients aged 65+ in the Chemotherapy Day Unit applying NHS Institute methodology (http://www.institute.nhs.uk 2016) and consisting of construct validity type questioning (how important/useful is this question) and unstructured feedback on what additional questions should be included. In addition the users on the steering group (older patients who were undergoing or had undergone chemo or radiotherapy) were consulted. As a result two questions were added ('is there anyone they can talk to about their cancer', and 'are they a caregiver for a dependent').
The project steering group, comprising oncologists, geriatricians, nurses, therapists, dieticians, palliative care, social care, patient representatives and voluntary organisations (Macmillan Cancer Support and Age UK) also contributed to the tested version.
An initial pilot was then conducted in 98 consented patients aged 65+ attending lymphoma clinic to identify any issues patients may have with completion. This showed a good rate of return (93%) with mean completion time of 11.5 AE 7.4 min. Most patients preferred to complete the questionnaire at home: 47% completed it at home and brought it to clinic, 7% completed it in clinic and 42% returned it by post following their clinic visit. These preferences informed application of CGA-GOLD in the main study.
Design
Subjects were older people presenting to cancer services within South-East London Cancer Network. The setting was the London teaching hospital where they were assessed. Patients were referred locally (urban with relatively low socioeconomics) and regionally (South England). They were posted project information with time to consider participation prior to written consent with no reminders. The study was approved by the national and institutional research ethics committees conforming to the provisions of the Declaration of Helsinki. The CGA-GOLD questionnaire is attached as an Appendix 1 -it is not copyrighted and freely available for use.
First phase testing was conducted in a prospective observational cohort of patients aged 65+ (Ethics 09H71865). Patients completed the CGA-GOLD questionnaire and received usual care from oncology AE any other clinical services. As this was an observation of usual care, CGA-GOLD data were not made available to oncologists. Questionnaires were posted and returned in a self-addressed envelope. Feasibility was evaluated by return rate, completion time, whether assistance was required, number of missed responses and prevalence of problems identified by CGA screening.
Second phase testing was conducted in the subsequently funded interventional cohort study evaluating the impact of geriatrician-delivered CGA in patients aged 70+ undergoing cancer treatment (Ethics 11/LO/0695) (Kalsi et al. 2015) . This publication provides more information about the design of the observation and intervention cohort. CGA-GOLD responses were reviewed by the geriatric team as part of the intervention. CGA need was categorised as low-risk (no self-reported comorbidities, CGA problems or recent hospital admissions and 'no/little difficulty' in function and QOL) or high-risk (≥1 comorbidity and/or CGA problems and/or 'quite a bit/very much' QOL or functional difficulties). Patients with one to two problems were 'possible need' and telephoned to clarify if these were already managed, could be managed remotely (e.g. dietician referral for weight loss), or required further indepth assessment and treatment. A related publication reporting this interventional study showed that CGA-GOLD categorised 54% as high-risk, 29% low-risk and 17% possible need (Kalsi et al. 2015) .
Low-risk patients received no further input but the geriatricians informed the oncologists of their fitness. Highrisk patients were invited for geriatrician-delivered CGA. To validate this method of using CGA-GOLD as a screening tool, a consecutive subset of questionnaires were independently reviewed and risk categorised by a senior specialist registrar (SpR) trained in geriatric-oncology and a Clinical Nurse Specialist (CNS) trained in geriatrics, and inter-rater agreement measured. The clinicians reviewed hospital clinical records, and in a further subset evaluated whether this changed their risk category from reviewing the questionnaire alone. Validity was based on whether a change in decision making occurred once supplementary information from the notes was examined. The outcome of telephone calls for those with 'possible need' was documented to further evaluate that risk category.
Data analysis
Demographics were collected using hospital electronic patient records. Data on CGA problems, time taken to complete the questionnaire and whether assistance was required were CGA-GOLD responses. Clinician risk assessments were data-based prospectively at the time of decision making. Inter-rater reliability was evaluated with kappa. SPSS v.19 statistical package (Chicago, Illinois, USA) was used for data analysis.
RESULTS
418/1002 (42%) of people sent the project information signed the consent for the observational study (February 2010 -October 2012 , and 417 completed CGA-GOLD first round with no prompting. Mean age was 73.9 years AE 5.4 (range 65-92), 56.9% were men. The commonest cancers were as follows: urological 24.4% (102), lung 17.9% (75), colorectal 17.5% (73), breast 14.6% (61), and gynaecological 9.3% (39). Metastatic malignancy was diagnosed in 41.6% at recruitment. Table 1 lists the prevalence of problems elicited from CGA-GOLD; all the CGA and comorbidity questions are listed, and some from EORTC-C30. Missing data equate to non-responses.
Mean completion time was 11.7 AE 7.9 min, and 86.3% (345) reported they completed CGA-GOLD without assistance. The overall rate of missing responses was low at 3.1%. The questions most often left blank were driving (there was no 'not applicable' option), and listing medications. .Patients reported marked rates of cardio-respiratory problems, diabetes, polypharmacy, recent decline in independent functioning, mobility difficulties, QOL impact, weight loss, incontinence, falls and depression. Certain questions flagged up a medical problem that should immediately prompt further clinical assessment, for example falls, pain limiting daily activities, dyspnoea on flat surfaces, current angina, poorly controlled hypertension or diabetes, bladder or bowel incontinence, depression, memory problems and delirium history. Combinations of factors provided more in-depth information (e.g. nutritional risk plus difficulty walking outside plus living alone, diarrhoea plus functional dependency, depression plus lack of social support), that would indicate a current need for further multidisciplinary support (e.g. occupational/physiotherapist, dietician, psychological support) .
Thirty-eight per cent (239/638) of people sent the project information returned the consent for the interventional cohort (August 2011 -February 2013 and 237/239 completed the questionnaire (age 76.6 AE 4.9, 70.7% male). The CNS and SPR independently reviewed the same questionnaires for 71 patients. The same decision was made in 87.3% (62/71) of patients with high inter-rater reliability (kappa = 0.80). The SpR and CNS independently reviewed questionnaires against the clinical notes and the results are presented in Table 2 . Decision making remained unchanged in 89% (73/82) for SPR and 90% (75/83) for CNS. Fifty-five patients were called to clarify possible need. 29% (16/55) were changed to low-risk, and none to high-risk, confirming that high need was not being missed. Change to lowrisk was generally because identified needs were being managed appropriately by others (e.g. already seeing dietician for weight loss, stroke disease already on appropriate management), or because symptoms had resolved.
DISCUSSION
This study demonstrates that the CGA-GOLD questionnaire is a feasible and useful CGA screening method for older people presenting to UK cancer services with the following findings:
• Self-completed patient focussed tool including comorbidites, CGA problems and QOL.
• Acceptable to older patients (99% return) who largely (86%) completed it without assistance.
• Brief (12 min).
• Low number of missing responses (3%).
• Feasibly completed at home by post or in clinic. • Identifies low-risk patients who do not need further medical review.
• Identifies specific problems that can be addressed by prompt clinical assessment in cancer clinic (e.g. BP control, polypharmacy, cardiac review).
• Clarifies need for further in-depth CGA and/or multidisciplinary involvement.
• Describes CGA problems early on that may affect how people cope with cancer treatment, but can be addressed through local resources.
Review of questionnaire responses by geriatrician nurse and registrar and phone calls demonstrated reliable risk categorisation even without notes review. Patients deemed to be high-risk were not being missed. Provider time to review and risk categorise the questionnaire was generally 1-2 min. Low-risk patients were quickly classified as not needing intervention, similarly high-risk patients with multiple comorbidities and functional difficulties were rapidly categorised for the optimisation pathway (which in this project was geriatrician-delivered). The intermediate group with a few problems (e.g. 1-2 comorbidities, mild functional difficulties) needed to have these discussed to see if they were ongoing. For this project this was done by a short phonecall, but within a service setting this discussion and any required intervention (e.g. dietician for weight loss, medication review) could practically occur in the oncology clinic in context of discussing cancer treatment.
The high inter-rater reliability between the two disciplines additionally supports the role of nurse specialists in administering and interpreting CGA-GOLD within cancer services. Service models where CGA screening is done by nurses or therapists with escalation for those requiring further input have been demonstrated in diverse healthcare settings (McCusker et al. 2003; Harari et al. 2007a,b; Morilla-Herrera et al. 2016) , and specifically in older cancer patients undergoing outpatient chemotherapy (Department of Health 2012; Kalsi et al. 2015) , and being admitted to oncology wards (Hamaker et al. 2011; Klepin et al. 2011) . The clinical nurse specialist in this study was trained in older persons care (Morilla-Herrera et al. 2016) and therefore could implement supportive pathways of care for those who screened as higher risk, but the medical optimisation was delivered by geriatricians and oncologists. Benefit of nurse CGA on clinical outcomes has been widely demonstrated, but is dependent on the role working within a multidisciplinary team.
Geriatric liaison to oncology services has been nationally resourced in a few countries (e.g. France, Belgium, Netherlands) but in many others (including the UK) this is not established. The method of assessing level of need was therefore largely protocolised according to the questionnaire responses for greater generalisability, and so, if needed can also be applied by clinicians who are not geriatricians such as oncology junior doctors and nurse specialists. In this situation, the escalation pathways would need to well-defined based on availability of local services. Patients identified as having more comorbidities and/or CGA needs would ideally be further reviewed by a geriatrics service rapidly to not delay cancer treatment. Geriatric-oncology service delivery models are beginning to emerge in the UK (Department of Health 2012) with clinical pathways linking screening tools to ongoing care (Kalsi et al. 2015) .
If dedicated geriatric liaison is not available however, a structured risk assessment such as CGA-GOLD can form a basis for rapid referral pathways to generic geriatric services (e.g. geriatrician CGA clinics, memory clinic, falls service), other medical specialities (e.g. cardiac, respiratory, diabetes), primary care, therapies or social support.
This study describes the coexisting needs of older people with cancer of all types. The patient-reported functional difficulties in activities of daily living, fatigue, poor nutrition and social isolation (11% had no-one to help out even for a few days) are all likely to impact how patients cope with treatment, including travelling to hospital appointments. Early identification of these issues should trigger arrangements for more practical support (e.g. home food delivery, social services for formal care packages, subsidised car transport, charitable organisations for befriending).
Prevalent problems such as urinary incontinence (a common CGA finding as previously documented in older cancer patients) (Wedding et al. 2007a,b) , falls (likewise 24% rate documented in oncology literature; Hurria et al. 2005) , and low mood can severely impact QOL, but are often overlooked in routine care. These can, however, be effectively managed alongside cancer treatment through relevant services (e.g. falls clinic, community continence services, GP/counselling). Several patients had chronic diseases that may decompensate as they undergo treatment (e.g. diabetes control worsening on steroids, medicated BP dropping with dehydration and causing dizziness/falls). If cancer services are aware of these comorbidites through CGA screening at the start of surgical and oncological treatment, they can proactively put in place measures to reduce toxicity (Kalsi et al. 2015) . An important aspect of this proactive care is to advise patients of how to deal with potential decompensations during and after treatment, for example (1) arranging insulin regimens with diabetic patients so they do not suffer hypoglycaemia with reduced oral intake, (2) informing hypertensive patients on symptoms of postural hypotension and how to reduce their antihypertensive medication dosage should they occur, (3) providing pelvic floor exercises, dietary/ fluid, containment and skin care advice to patients at risk of developing urinary and faecal incontinence from chemo or radiotherapy. Most published cancer comorbidity studies are retrospective using data derived from cancer registers rather than directly from patients. CGA-GOLD, for instance asked whether patients were short of breath walking on flat surfaces rather than if they had a diagnosis of lung disease, thus capturing relevant clinical impact. Although not formally measured, many comorbidities identified in this study were newly detected. A recent US National Cancer Institute Index study found that 10.1% of breast cancer patients had ≥1 undetected comorbidity associated with older age and tumour factors; following adjustment for these factors undetected comorbidity remained significantly associated with lower odds of receiving adjuvant chemotherapy in stage 1-111 cancer (Griffiths et al. 2014) This reinforces the message that comorbidity should be medically optimised first before influencing decisions towards less aggressive treatment. Older people are also likely to have chemotherapy discontinued or dose-reduced for low-grade toxicities, presenting a further role for CGA optimisation during treatment to increase the odds of completion of curative treatment (Kalsi et al. 2014) . This study is limited by being performed in a single site and the results require validation in other settings. The number of assessors of validity and reliability was limited to two and though systematic methods were used, other assessors may potentially have assessed responses differently. Comorbidities depended on reliable self-report; however a recent study compared self-reported comorbidity using a patient questionnaire against traditional medical interview in patients with skin cancer and showed that the questionnaire identified comorbidity in more patients (88.6% versus 79.5%), and when there were discordant observations, was five times more likely to identify the comorbidity (Lee et al. 2015) . The majority of questionnaire responses were validated as reliable having been taken from evidence-based sources, but the memory question could be reinforced with another measure such as a clock drawing test (Shulman 2000) , though that would have lengthened the completion time. The clinical validation of CGA GOLD used the hospital notes as corroboration with the limitation that some of the data provided within the CGA-GOLD may not be within the notes (though this is also what makes it potentially useful).
This study demonstrates the performance of a CGA screening tool in the pressurised clinical setting of a National Health Service and adds to existing data on screening tools. There are now consistent recommendations from scientific consensus groups and national bodies to use this type of screening in older people to identify fit patients and to optimise those with identified problems. Further research should focus on service development around the implementation of screening tools within health care systems. The processes and outcomes of integrating CGA-GOLD (and any other relevant tools) into oncological clinical practice including how further medical, comorbidity and/or multidisciplinary management is triggered needs further evaluation. Outcomes would include whether:
• oncology decision making is altered by this approach;
• the quality of patient-centred data informing oncology and surgical MDT meetings and clinics is enhanced;
• patients are more likely to complete treatment as planned;
• toxicity severity and patient quality of life impact is reduced.
Improved cancer care for older people has become a healthcare priority in the UK and elsewhere. The 2015 SIOG consensus recommends that a screening tool be used in all oncology practices to identify fit older people who should receive full treatment, particularly in view of population studies showing an overall tendency to undertreat cancer in older people (Decoster et al. 2015) . The UK Department of Health's report 'Cancer Services Coming of Age' (Department of Health 2012) highlights the need to improve outcomes for older people with cancer and calls for innovative change. It stresses the benefits of engaging elderly care specialists in cancer care, and utilising CGA, as an assessment that can impact positively on treatment decision making and general quality of care through clinical interventions. Not all older people with cancer have complex needs, requiring specialist assessment and intervention and so the use of a screening questionnaire would assist the allocation of finite resource to the most appropriate patient group, without compromising care. The CGA-GOLD questionnaire has demonstrated it is a valid and reliable tool that can be feasibly implemented to the UK NHS setting. 
